Hanall Biopharma Launches 'Melaone Extended-Release Tablets' for Insomnia Treatment

[Asia Economy Reporter Chunhee Lee] HanAll Biopharma announced on the 13th that it has launched the insomnia treatment drug "Melaone Extended-Release Tablets 2mg (active ingredient melatonin)".

Melaone is a synthetic drug chemically identical to melatonin, a hormone naturally produced in the body that induces sleep. It is used as a treatment for short-term therapy in insomnia patients aged 55 and older with decreased sleep quality. As an extended-release formulation that continuously releases melatonin throughout the entire sleep period, similar to endogenous melatonin secretion, it readjusts the sleep-wake cycle according to the biological rhythm, improving sleep quality.

Additionally, Melaone is a non-habit-forming, non-psychotropic drug without dependence or tolerance, and even if treatment is discontinued, it has fewer side effects such as rebound insomnia or withdrawal symptoms. Therefore, long-term prescriptions up to 13 weeks are possible. Patients should take one tablet orally once a day, after meals, 1 to 2 hours before bedtime, without chewing or crushing the tablet.

According to the Health Insurance Review & Assessment Service, the number of insomnia patients in Korea has steadily increased, reaching approximately 680,000 in 2021. According to the market research firm IMS, the domestic melatonin market grew rapidly at an average annual rate of over 18%, from about 5.5 billion KRW in 2018 to about 10 billion KRW in 2021.

Seungwon Jeong, CEO of HanAll Biopharma, said, "Insomnia is one of the common diseases among modern people," adding, "We expect Melaone to help improve sleep quality and alleviate patients' economic burden with a reasonable price compared to the original drug."

This content was produced with the assistance of AI translation services.